HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Beth Butler Selected Research

reparixin

11/2021A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).
10/2020A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
1/2020Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Beth Butler Research Topics

Disease

3Breast Neoplasms (Breast Cancer)
11/2021 - 01/2020
1Triple Negative Breast Neoplasms
11/2021

Drug/Important Bio-Agent (IBA)

3reparixinIBA
11/2021 - 01/2020
1Paclitaxel (Taxol)FDA LinkGeneric
11/2021

Therapy/Procedure

1Drug Therapy (Chemotherapy)
11/2021
1Therapeutics
11/2021